Literature DB >> 27926887

The Application of Genomics in Diabetes: Barriers to Discovery and Implementation.

James S Floyd1, Bruce M Psaty2,3,4.   

Abstract

The emerging availability of genomic and electronic health data in large populations is a powerful tool for research that has drawn interest in bringing precision medicine to diabetes. In this article, we discuss the potential application of genomics to the prediction, prevention, and treatment of diabetes, and we use examples from other areas of medicine to illustrate some of the challenges involved in conducting genomics research in human populations and implementing findings in practice. At this time, a major barrier to the application of genomics in diabetes care is the lack of actionable genomic findings. Whether genomic information should be used in clinical practice requires a framework for evaluating the validity and clinical utility of this approach, an improved integration of genomic data into electronic health records, and the clinical decision support and educational resources for clinicians to use these data. Efforts to identify optimal approaches in all of these domains are in progress and may help to bring diabetes into the era of genomic medicine.
© 2016 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2016        PMID: 27926887      PMCID: PMC5079615          DOI: 10.2337/dc16-0738

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  163 in total

1.  Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.

Authors:  A Holstein; A Plaschke; M Ptak; E-H Egberts; J El-Din; J Brockmöller; J Kirchheiner
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

2.  A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors:  Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

3.  The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.

Authors:  Giorgio Sesti; Emanuela Laratta; Marina Cardellini; Francesco Andreozzi; Silvia Del Guerra; Concetta Irace; Agostino Gnasso; Maria Grupillo; Renato Lauro; Marta Letizia Hribal; Francesco Perticone; Piero Marchetti
Journal:  J Clin Endocrinol Metab       Date:  2006-04-04       Impact factor: 5.958

4.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Authors:  Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

5.  Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study.

Authors:  Tanja Dujic; Kaixin Zhou; Louise A Donnelly; Roger Tavendale; Colin N A Palmer; Ewan R Pearson
Journal:  Diabetes       Date:  2014-12-15       Impact factor: 9.461

6.  Primary care physicians' knowledge of and experience with pharmacogenetic testing.

Authors:  S B Haga; W Burke; G S Ginsburg; R Mills; R Agans
Journal:  Clin Genet       Date:  2012-07-03       Impact factor: 4.438

Review 7.  Genome-wide association studies in pharmacogenomics: successes and lessons.

Authors:  Alison A Motsinger-Reif; Eric Jorgenson; Mary V Relling; Deanna L Kroetz; Richard Weinshilboum; Nancy J Cox; Dan M Roden
Journal:  Pharmacogenet Genomics       Date:  2013-08       Impact factor: 2.089

Review 8.  Diabetes: Advances in Diagnosis and Treatment.

Authors:  David M Nathan
Journal:  JAMA       Date:  2015-09-08       Impact factor: 56.272

9.  Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.

Authors:  Yan Feng; Guangyun Mao; Xiaowei Ren; Houxun Xing; Genfu Tang; Qiang Li; Xueqi Li; Lirong Sun; Jinqui Yang; Weiqing Ma; Xiaobin Wang; Xiping Xu
Journal:  Diabetes Care       Date:  2008-07-03       Impact factor: 17.152

10.  Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems.

Authors:  L J Rasmussen-Torvik; S C Stallings; A S Gordon; B Almoguera; M A Basford; S J Bielinski; A Brautbar; M H Brilliant; D S Carrell; J J Connolly; D R Crosslin; K F Doheny; C J Gallego; O Gottesman; D S Kim; K A Leppig; R Li; S Lin; S Manzi; A R Mejia; J A Pacheco; V Pan; J Pathak; C L Perry; J F Peterson; C A Prows; J Ralston; L V Rasmussen; M D Ritchie; S Sadhasivam; S A Scott; M Smith; A Vega; A A Vinks; S Volpi; W A Wolf; E Bottinger; R L Chisholm; C G Chute; J L Haines; J B Harley; B Keating; I A Holm; I J Kullo; G P Jarvik; E B Larson; T Manolio; C A McCarty; D A Nickerson; S E Scherer; M S Williams; D M Roden; J C Denny
Journal:  Clin Pharmacol Ther       Date:  2014-06-24       Impact factor: 6.875

View more
  6 in total

Review 1.  The Continuing Evolution of Precision Health in Type 2 Diabetes: Achievements and Challenges.

Authors:  Yuan Lin; Jennifer Wessel
Journal:  Curr Diab Rep       Date:  2019-02-26       Impact factor: 4.810

2.  Systems Biology to Address Unmet Medical Needs in Neurological Disorders.

Authors:  Masha G Savelieff; Mohamed H Noureldein; Eva L Feldman
Journal:  Methods Mol Biol       Date:  2022

3.  Effects of a Lifestyle-Modification Program on Blood-Glucose Regulation and Health Promotion in Diabetic Patients: A Randomized Controlled Trial.

Authors:  Sang-Wook Shin; Su-Jin Jung; Eun-Soo Jung; Ji-Hyun Hwang; Woo-Rim Kim; Byung-Ok So; Byung-Hyun Park; Seung-Ok Lee; Baik-Hwan Cho; Tae-Sun Park; Young-Gon Kim; Soo-Wan Chae
Journal:  J Lifestyle Med       Date:  2020-07-31

4.  Systems and precision medicine approaches to diabetes heterogeneity: a Big Data perspective.

Authors:  Enrico Capobianco
Journal:  Clin Transl Med       Date:  2017-07-25

Review 5.  Precision medicine in diabetes prevention, classification and management.

Authors:  Fangying Xie; Juliana Cn Chan; Ronald Cw Ma
Journal:  J Diabetes Investig       Date:  2018-04-25       Impact factor: 4.232

Review 6.  Precision Health Care Elements, Definitions, and Strategies for Patients with Diabetes: A Literature Review.

Authors:  Satriya Pranata; Shu-Fang Vivienne Wu; Javad Alizargar; Ju-Han Liu; Shu-Yuan Liang; Yu-Ying Lu
Journal:  Int J Environ Res Public Health       Date:  2021-06-17       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.